Selective inhibition of BET bromodomains P Filippakopoulos, J Qi, S Picaud, Y Shen, WB Smith, O Fedorov, ... Nature 468 (7327), 1067-1073, 2010 | 4274 | 2010 |
Histone recognition and large-scale structural analysis of the human bromodomain family P Filippakopoulos, S Picaud, M Mangos, T Keates, JP Lambert, ... Cell 149 (1), 214-231, 2012 | 1722 | 2012 |
Targeting bromodomains: epigenetic readers of lysine acetylation P Filippakopoulos, S Knapp Nature reviews Drug discovery 13 (5), 337-356, 2014 | 1311 | 2014 |
Protein production and purification Architecture et Fonction des Macromolécules Biologiques Vincentelli Renaud 4 ... Nature methods 5 (2), 135-146, 2008 | 1020 | 2008 |
The promise and peril of chemical probes CH Arrowsmith, JE Audia, C Austin, J Baell, J Bennett, J Blagg, C Bountra, ... Nature chemical biology 11 (8), 536-541, 2015 | 841 | 2015 |
Critical residues for structure and catalysis in short-chain dehydrogenases/reductases C Filling, KD Berndt, J Benach, S Knapp, T Prozorovski, E Nordling, ... Journal of Biological Chemistry 277 (28), 25677-25684, 2002 | 674 | 2002 |
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs KL Kavanagh, K Guo, JE Dunford, X Wu, S Knapp, FH Ebetino, ... Proceedings of the National Academy of Sciences 103 (20), 7829-7834, 2006 | 649 | 2006 |
Bromodomains as therapeutic targets S Muller, P Filippakopoulos, S Knapp Expert reviews in molecular medicine 13, e29, 2011 | 547 | 2011 |
Large-scale structural analysis of the classical human protein tyrosine phosphatome AJ Barr, E Ugochukwu, WH Lee, ONF King, P Filippakopoulos, I Alfano, ... Cell 136 (2), 352-363, 2009 | 544 | 2009 |
Linear motif atlas for phosphorylation-dependent signaling ML Miller, LJ Jensen, F Diella, C Jørgensen, M Tinti, L Li, M Hsiung, ... Science signaling 1 (35), ra2-ra2, 2008 | 527 | 2008 |
Copper is required for oncogenic BRAF signalling and tumorigenesis DC Brady, MS Crowe, ML Turski, GA Hobbs, X Yao, A Chaikuad, S Knapp, ... Nature 509 (7501), 492-496, 2014 | 518 | 2014 |
Small-molecule inhibition of BRDT for male contraception MM Matzuk, MR McKeown, P Filippakopoulos, Q Li, L Ma, JE Agno, ... Cell 150 (4), 673-684, 2012 | 509 | 2012 |
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain S Picaud, C Wells, I Felletar, D Brotherton, S Martin, P Savitsky, ... Proceedings of the National Academy of Sciences 110 (49), 19754-19759, 2013 | 480 | 2013 |
The bromodomain interaction module P Filippakopoulos, S Knapp FEBS letters 586 (17), 2692-2704, 2012 | 453 | 2012 |
Trends in kinase drug discovery: targets, indications and inhibitor design MM Attwood, D Fabbro, AV Sokolov, S Knapp, HB Schiöth Nature Reviews Drug Discovery 20 (11), 839-861, 2021 | 444 | 2021 |
Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy KVM Huber, E Salah, B Radic, M Gridling, JM Elkins, A Stukalov, ... Nature 508 (7495), 222-227, 2014 | 442 | 2014 |
PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers L Brault, C Gasser, F Bracher, K Huber, S Knapp, J Schwaller haematologica 95 (6), 1004, 2010 | 423 | 2010 |
Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? Z Zhao, H Wu, L Wang, Y Liu, S Knapp, Q Liu, NS Gray ACS chemical biology 9 (6), 1230-1241, 2014 | 417 | 2014 |
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases O Fedorov, B Marsden, V Pogacic, P Rellos, S Müller, AN Bullock, ... Proceedings of the National Academy of Sciences 104 (51), 20523-20528, 2007 | 416 | 2007 |
Crystal structure of the tetrameric Mad1–Mad2 core complex: implications of a ‘safety belt’binding mechanism for the spindle checkpoint L Sironi, M Mapelli, S Knapp, A De Antoni, KT Jeang, A Musacchio The EMBO journal, 2002 | 394 | 2002 |